Meeting
2015 ASCO Annual Meeting
Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.
Authors
Zofia Piotrowska
Massachusetts General Hospital Cancer Center, Boston, MA
Zofia Piotrowska , Daniel Botelho Costa , Mark Huberman , Geoffrey R. Oxnard , Justin F. Gainor , Rebecca Suk Heist , Alona Muzikansky , Alice Tsang Shaw , Matthew J. Niederst , Linnea Fulton , Jeffrey A. Engelman , Lecia V. Sequist
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01854034
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8015)
DOI
10.1200/jco.2015.33.15_suppl.8015
Abstract #
8015
Poster Bd #
337
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy.
First Author: Anna Rachel Minchom
Poster
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
First Author: Helena Alexandra Yu
Poster
2024 ASCO Annual Meeting
A multicenter, prospective phase II trial of first-line osimertinib treatment for patients with poor performance status and EGFR mutation–positive non-small cell lung cancer (OPEN/TORG2040).
First Author: Nobuaki Mamesaya
Poster
2024 ASCO Annual Meeting
High-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study.
First Author: Haiyang Chen